Clinicopathological and treatment characteristics
| Characteristics | Study population (N=169) N (%) |
| Sex | |
| Female | 78 (46.2) |
| Male | 91 (53.8) |
| Age (years) | |
| <70 | 118 (69.8) |
| ≥70 | 51 (30.2) |
| ECOG PS | |
| 0 | 104 (61.5) |
| ≥1 | 65 (38.5) |
| Primary tumor resection | |
| No | 4 (2.4) |
| Yes | 165 (97.6) |
| Primary tumor sidedness | |
| Left | 49 (29.0) |
| Right | 120 (71.0) |
| RAS and BRAF mutational status | |
| All wild-type | 65 (38.5) |
| RAS mutated | 48 (28.4) |
| BRAF mutated | 56 (33.1) |
| Synchronous metastases | |
| No | 76 (45.0) |
| Yes | 93 (55.0) |
| Liver metastases | |
| No | 110 (65.1) |
| Yes | 59 (34.9) |
| Lung metastases | |
| No | 129 (76.3) |
| Yes | 40 (23.7) |
| Lymph nodal metastases | |
| No | 59 (34.9) |
| Yes | 110 (65.1) |
| Peritoneal metastases | |
| No | 100 (59.2) |
| Yes | 69 (40.8) |
| Bone metastases | |
| No | 159 (94.1) |
| yes | 10 (5.9) |
| No of metastatic sites | |
| 1 | 68 (40.2) |
| ≥2 | 101 (59.8) |
| Prior systemic treatment for metastatic disease | |
| No | 36 (21.3) |
| Yes | 133 (78.7) |
| Time from metastatic condition to ICI treatment start | |
| <18 months | 114 (67.5) |
| ≥18 months | 55 (32.5) |
| ICI regimen | |
| Anti-PD-1 | 116 (68.6) |
| Anti-CTLA-4+ anti-PD-1 | 53 (31.4) |
ICI, immune checkpoint inhibitor.